Search results
Displaying Results 1331-1340 of 13853 for "❤️推荐陈书记您轻点儿，请访问 【】❤️推荐"
FountainVest buys China logistics business
FountainVest Partners has agreed to acquire a majority stake in China-based CJ Rokin Logistics from Korea’s CJ Logistics for KRW733.8 billion ($661.3 million).
New Frontier Japan targets $94m for second fund
New Frontier Japan Investment (NFJI), a lower middle-market Japanese private equity firm, is looking to raise JPY10 billion ($94.4 million) for its second fund.
China's WuXi Diagnostics raises $150m
WuXi Diagnostics, a joint venture China diagnostics business set up by Hong Kong-listed pharmaceutical outsourcing giant WuXi AppTec and US-based Mayo Clinic has completed a $150 million Series B funding round.
Q&A: Affirma Capital's Ivo Philipps
Affirma Capital came into being 18 months ago as Standard Chartered’s private equity team spun out with most of the remaining balance sheet assets. COO Ivo Philipps explains the middle and back office transition
China's Fresh Capital hits $93m first close on Fund II
Fresh Capital, a Shanghai-based venture capital firm, has reached a first close of RMB600 million ($93 million) on its second renminbi-denominated fund.
VC-backed Appier files for Japan IPO
Appier, a Taiwan-based advertising technology provider, has filed for a JPY26.4 billion ($250 million) Japan IPO. It sets up exits for several VC investors, including Sequoia Capital.
Fund focus: LPs endorse Ocean Link's China tourism, tech thesis
Ocean Link has raised $580 million for a second fund targeting China travel, tourism and consumer technology assets, but the firm believes co-investment could take aggregate deployment to $1.4 billion
China's Clover Biopharmaceuticals gets $230m Series C
Chengdu-based Clover Biopharmaceuticals has raised $230 million in Series C funding led by GL Ventures and Temasek Holdings. Oceanpine Capital, OrbiMed, and Delos Capital all re-upped.
Primavera-led consortium takes control of Zhaopin
A consortium led by Primavera Capital has agreed to acquire a controlling position in Chinese recruitment website Zhaopin at an implied valuation of A$2.2 billion ($1.7 billion).
China's AnchorDx completes $40m Series C
AnchorDx, a China-based medical technology developer focused on DNA sequencing and diagnostics, has raised a $40 million Series C round led by OrbiMed and WuXi Huiying Investment.